EMA Authorised: Tevagrastim (filgrastim) — Teva GmbH

View source ↗

Summary

The EMA authorised Tevagrastim (filgrastim) by Teva GmbH for cancer-related indications (and related hematopoietic stem cell transplantation use).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Tevagrastim (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Teva GmbH. Decision date: 21/08/2024